/Investor DB

ACORN BIOVENTURES — 2022 Investments

5 investments dated 2022 · listed companies and verified rows first · show all

Liquid Instrumentsliquidinstruments.comin𝕏Sep 2022 · $28.5M

Liquid Instruments develops Moku, a reconfigurable integrated test system for complex research and development applications.

Deep TechDeveloper ToolsEnterprise SoftwareHardware

Daniel Shaddock(CEO)inDanielle Wuchenich(Chief Operating Officer)in

Co-investorsAnzu PartnersMA Growth VenturesSignificant VenturesAcorn CapitalLockheed Martin Ventures

Mokumoku.gg𝕏Sep 2022 · $28.5M

Moku creates Moki, a collection of 8887 hand-assembled NFT characters built from 900+ traits, and develops games around them including an AI Fantasy Arena, a snack-combining puzzler, and an async autobattler.

AI & Machine LearningCrypto & Web3Gaming

Bruce Wasicsko(Founder)in

Co-investorsArca FundsBankless VenturesBig Brain HoldingsBlocktower CapitalContango Digital AssetsFormless Capital+4 more

Mx51mx51.comin𝕏Jul 2022 · $32.5M

mx51 provides a white-label merchant dashboard portal that gives payment providers' customers centralized access to real-time transaction reporting, analytics, and service management across multiple payment channels.

Data & InfrastructureEnterprise SoftwareFintechRetail TechSaaSSydney, AU

Victor Zheng(Chief Executive Officer and Co-Founder)inMagnus Hsu(Chief Operating Officer and Co-Founder)inVarghese Mathew(Chief Customer Officer)in

Co-investorsArtesianRampersandReinventure GroupSixThirty VenturesAcorn CapitalCultivation Capital

Neuron23neuron23.cominMar 2022 · $100M

Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.

AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US

Nancy Stagliano(CEO)in

Co-investorsHBM Healthcare InvestmentsHBM PartnersKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartners+2 more

ONK Therapeuticsonktherapeutics.comSeries A · Jan 2022 · $22M

ONK Therapeutics develops off-the-shelf natural killer (NK) cell therapies for cancer, using a proprietary engineering platform to enhance NK cell function, tumor homing, persistence, and resistance to exhaustion.

Biotech

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.